Cure8 research brief
Wearables could allow continuous, noninvasive monitoring that may detect IBD flares earlier and help distinguish inflammatory from noninflammatory symptoms, which matters for timely treatment decisions and avoiding unnecessary therapies. The field is promising but still early—more trials are needed before routine use.
Patients with IBD, clinicians treating IBD, researchers and device developers, clinicians interested in motility and gut–brain disorders.
This review summarizes how wearable devices are being used to monitor gastrointestinal diseases.
It highlights that wearables can capture physiologic (heart rate, activity, sleep), biochemical (sweat biosensors measuring inflammatory analytes such as calprotectin), and acoustic or electrogastrographic signals relevant to IBD, disorders of gut–brain interaction, motility, and liver disease recovery.
The authors report that in inflammatory bowel disease, some wearable-derived physiologic changes may occur before symptomatic or inflammatory flares and could help distinguish inflammatory versus noninflammatory causes of symptoms, but most evidence so far is observational and lacks validated clinical thresholds.
Key gaps noted include a need for prospective trials, validated actionable thresholds for wearable signals, workflow integration, and patient-centered implementation before routine clinical use.
Evidence is predominantly observational and lacks validated clinical thresholds; the review calls for prospective trials and implementation research. The content is based on the article abstract rather than a full guideline or clinical trial report.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Competing Interests: SPB reports no conflicts of interest. RPH reports Advisory Boards: Bristol Meyer Squibb, Abbvie, Salvo Health; Speaker: Sanofi; Research Support: Intralytix, Enlisense, Janssen, Crohn’s and Colitis Foundation, National Institute of Health.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive imaging that better separates inflammation from fibrosis and detects penetrating complications could change monitoring and treatment decisions in IBD and reduce radiation exposure for patients needing...
Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.
Better detection of enteric infections during suspected IBD flares could help avoid unnecessary escalation of immunosuppressive therapy and guide appropriate antibiotic use. This review suggests MPCR finds more pathogens...
